Silver Book Fact

A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.

Mobley, Lee R., Thomas J. Hoerger, John S. Wittenborn, Debroah A. Galuska, and Jaya K. Rao. Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate. Medical Decision Making. 2006; 26(2): 194-206. http://mdm.sagepub.com/cgi/content/abstract/26/2/194

Reference

Title
Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate
Publication
Medical Decision Making
Publication Date
2006
Authors
Mobley, Lee R., Thomas J. Hoerger, John S. Wittenborn, Debroah A. Galuska, and Jaya K. Rao
Volume & Issue
Volume 26, Issue 2
Pages
194-206
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by…